PubMed · 9782406
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
G F Hasse. 1998. [Correction offered].. https://pubmed.ncbi.nlm.nih.gov/9782406/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Introduction and application of new technologies in the Dutch health care system will be less straightforward in the future than they were in the past. The pressure to contain health care expenditure has increased, also because of European agreements about adequate financing of collective spending. This will make initiators and producers of new technologies more critical towards technologies currently in development and urge them to specifically introduce technologies with a relatively favourable cost effectiveness profile. Whether new technologies will be used to a large extent will increasingly depend on the parties in health care at the regional and practice levels, who will assume a more important role in resource allocation in health care. On the other hand, they will be made more accountable for their decisions and will have to demonstrate their contribution to efficiency in health care.
Explore the source record for details and available documents.
Vaccines are the most popular preventive intervention world-wide and are socially useful interventions. As with all social programmes, the effects of vaccines must be carefully assessed. Their economic significance lies partly in the burden of disease that can be avoided and partly in the competition for resources between vaccines and other interventions. Classic methods of economic evaluation depend on the evaluation of effectiveness and safety of each vaccine being evaluated and can indicate whether vaccination represent a good return for investment, especially if the wider social perspective is taken into account. The use of economic logic can also be applied to prioritize research into vaccines, both on the basis of ability of the target population to benefit and of the availability of good quality evidence.